Clinical trial · Interventional
Physical Activity to Reduce Joint Pain During Aromatase Inhibitor Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
For post-menopausal women diagnosed with hormone-receptor positive breast cancer tumors, aromatase inhibitors (AIs) are the standard adjuvant hormone treatment to prolong disease-free survival and time-to-recurrence. Unfortunately, joint pain/stiffness/achiness (arthralgia) is a common side-effect of AIs. This "proof-of-concept" study explores how an evidence-based physical activity (PA) program- the Arthritis Foundation's Walk with Ease (WWE) program- can be adapted for breast cancer survivors on AI therapy to: 1) Help them maintain or achieve recommended levels of PA, 2) reduce their joint pain/stiffness/achiness, and 3) thereby enable them to remain on AI therapy as prescribed.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Joint Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Walk with Ease | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Walking
- description
- Walk with Ease
- interventionNames
- Behavioral: Walk with Ease
- type
- NO_INTERVENTION
- label
- Wait list control
- description
- Wait list control receiving the active intervention 6 weeks later.
Primary outcomes (1)
- measure
- Self-reported joint pain
- timeFrame
- 6 weeks
- description
- A valid and reliable 10cm Visual Analog Scale will be used to assess self-reported joint pain. This scale has been used in numerous trials.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Taking an aromatase inhibitor as adjuvant treatment for State I, II, or II breast cancer for at least 4 weeks * Experiencing more than mild joint pain/symptoms * 21 or older * have permission from physician to engage in moderate intensity physical activity Exclusion Criteria: * Undergoing chemotherapy and/or radiation therapy at any time during the study period * Scheduled for major surgery during the study period * Presently engaged in high levels of physical activity on a daily basis * Less than 21 years of age * Unable to walk or engage in moderate intensity physical activity
References
Publications (0)
Data not yet available